Rising Stars Outlook 2016: New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH)

Description: Non-Alcoholic SteatoHepatitis (NASH) is an unmet medical need and is becoming the leading cause of liver transplant. No FDA-approved therapies and a meager diagnosis, it poses a unique challenge in the design of studies for NASH. Therefore, there is a worldwide need for new therapies to treat the global epidemic of NASH and the cost to society will be huge if it is not addressed in the upcoming years. Besides, scarcity of treatment options, there is also an urgent unmet need to develop biomarkers that facilitate the diagnosis, identification of populations at risk, assessment of disease progression or regression, and/or response to treatment. The potential market is gigantic with analysts predicting north of $35bn by 2025.

Many small players are currently developing drugs on their own and with such a large unmet need, market potential and disease heterogeneity, we expect many Giants to join this race and thus, we can see more Licensing deals/ M&A activity on the horizon. In light of recent developments in NASH, we have added few in-depth coverage of companies which either target early-stage NASH, late-stage NASH, or large pts pool-NAFLD in our Outlook this year.

Contents:

1. Conatus Pharmaceuticals (CNAT)
   - Emricasan: Disease Modifying Potential across the Spectrum of Liver Diseases
   - Key Milestones (CNAT)
   - Trends in overall population driven by significant improvement in MELD =15 subgroup
     Figure 1 Conatus Pharma
   - Emricasan: Data From Phi, Liver Cirrhosis Trial (3-Month)
     Table 1 Conatus Pharma
   - Phiib, Encore Program In Different Etiologies & Stages
     Table 2 Conatus Pharma
   - Competitive Landscape (Late-Stage Pipeline) For Nash
     Figure 2 Conatus Pharma
   - Emricasan: Medical Need And Market Opportunities
     Figure 3 Conatus Pharma
   - Emricasan: A Potent Inhibitor Of Apoptotic And Inflammatory Caspases
     Figure 4 Conatus Pharma
   - Emricasan: Phase II, Liver Cirrhosis Trial (3 Months)
     Figure 5 Conatus Pharma
   - Emricasan: Phase II Data @ Easl, 2015
     Figure 6 Conatus Pharma
   - Emricasan: Phase II Data @ Aasld, 2015
     - Changes in Clinical, Biochemical, and Biomarker parameter from Baseline

2. Galectin Therapeutics (GALT)
   - Reversing Late-Stage NASH (Advanced Fibrosis)
   - Key Milestones (GALT)
   - Competitive Landscape (Late-Stage Pipeline) For Nash
   - Role Of Galectin-3 In Pathophysiology Of NASH And Fibrogenesis
     - Phase II Trial Designs: Nash-Cx (W/ Cirrhosis) & Nash-Fx (W/ Advanced Fibrosis)
     - Gr-Md-02: Phi Study – Serum Biomarkers Evaluation
       Figure 4 Galectin Therapeutics
     - Gr-Md-02: Preclinical Data – TX Effect On Nash With Fibrosis
       Figure 5 Galectin Therapeutics
   - Pipeline Portfolio

   - Key Milestones (GLMD)
   - Table 1 Galmed Pharmaceuticals
   - Competitive Landscape (Late-Stage Pipeline) For Nash
4. Genfit SA (GNFT)
- GNFT offers Remarkable NASH Treatment Package: Robust Drug + Non-Invasive Biomarker Test
- Key Milestones (GNFT)
- Figure 1 Genfit SA
Golden-505: Comparison With Other Phi5 Studies
- Figure 2 Genfit SA
Golden-505: Comparison With Other Phi5 Studies
- Table 1 Genfit SA
Competitive Landscape (Late-Stage Pipeline) For Nash
- Table 1 Genfit SA
Competitive Landscape (Late-Stage Pipeline) For Nash
- Figure 3 Genfit SA
Elafibranor: Ppar Regulates Numerous Pathways Essential In Nash
- Clinical Development
-Figure 4 Genfit SA
Elafibranor: Phase Iii Trial Design
- Figure 5A Genfit SA
Golden-505: Improvement In Cardio-Metabolic And Glycemic Parameters
- Figure 6 Genfit SA
Efficacy Of Gft505 In Animal Models Of NaflD/ Nash And Liver Fibrosis
- Figure 7 Genfit SA
Efficacy Of GFT505 In Animal Models Of NaflD/ Nash And Liver Fibrosis
- Figure 8 Genfit SA
Effects Of GFT505 In Rats With Established Hepatic Fibrosis
- Figure 8 Genfit SA
Effects Of GFT505 In Rats With Established Hepatic Fibrosis

5. Intercept Pharmaceuticals (ICPT)
- Mixed Data and Pricing/Reimbursement Concerns may Limit OCA’s Market Potential
- Figure 1 Intercept Pharmaceuticals
Global PBC Patient Waterfall
- Key Milestones (ICPT)
- Figure 2 Intercept Pharmaceuticals
Flint Study Results: Improvement In NAS, FIBROSIS, And NASH Resolution
- Table 1 Intercept Pharmaceuticals
Competitive Landscape (Late-Stage Pipeline) For Nash
- Figure 3 Intercept Pharmaceuticals
FXR Is Central To A Multitude Of Pathways
- Figure 5 Intercept Pharmaceuticals
Poise Study: Met The Primary Endpoint As Early As 2 Weeks
- Figure 6

6. Intercept Pharmaceuticals
FLINT STUDY: RESPONSE RATES, FIBROSIS IMPROVEMENT - KEY MILESTONES
Figure 1 Tobira Therapeutics
CENTAUR - PHIIB Clinical Trial Vs. Other Published Phiib Studies In Nash (TBRA) Tobira Therapeutics
Cenicriviroc (CVC): A Potent Inhibitor Of Infiltration Of Pro-Inflammatory Monocytes
Tobira Therapeutics
Drugs In Development For Nash
Ordering:

Order Online - http://www.researchandmarkets.com/reports/3638080/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

| Product Name: | Rising Stars Outlook 2016: New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH) |
| Web Address: | [http://www.researchandmarkets.com/reports/3638080/](http://www.researchandmarkets.com/reports/3638080/) |
| Office Code: | SCH3G8QC |

Product Formats
Please select the product formats and quantity you require:

- **Quantity**
  - Hard Copy: ☐ USD 1800 + USD 58 Shipping/Handling
  - CD-ROM: ☐ USD 1800 + USD 58 Shipping/Handling
  - Electronic (PDF) - Single User: ☐ USD 1800
  - Electronic (PDF) - Site License: ☐ USD 3600
  - Electronic (PDF) - Enterprisewide: ☐ USD 5400

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

| Title: | Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐ |
| First Name: | ___________________________ |
| Last Name: | ___________________________ |
| Email Address: * | ___________________________ |
| Job Title: | ___________________________ |
| Organisation: | ___________________________ |
| Address: | ___________________________ |
| City: | ___________________________ |
| Postal / Zip Code: | ___________________________ |
| Country: | ___________________________ |
| Phone Number: | ___________________________ |
| Fax Number: | ___________________________ |
Title: Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World